FY23 revenue view is is based on sacral neuromodulation and Bulkamid revenue each growing 25% compared to FY22. Sees FY23 sacral neuromodulation revenue $277.5M and Bulkamid revenue $64.5M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AXNX: